Volver a Agenda
Session Chair(s)
Chandra Vemavarapu, PHD
Associate Director
Bristol-Myers Squibb Company, United States
Learning Objective : Discuss current trends in the development of fixed-dose combination products including guidelines, challenges, and opportunities; Describe best practices in the development and registration of combination products; Influence continuous improvement in the regulatory framework around combination products.
Speaker(s)
Global Regulatory Framework and the CMC Challenges and Considerations for Fixed-Dose Combbinations
Xiling Song, MS
Genentech, A Member of the Roche Group, United States
Senior Quality Product Leader
FDA Perspective
George Lunn, PHD
FDA, United States
Chemist, ONDQA, OPS, CDER
¿Tiene una cuenta?